Metabolomics in pancreatic cancer biomarkers research

IF 3.5 4区医学 Q2 ONCOLOGY Medical Oncology Pub Date : 2016-11-02 DOI:10.1007/s12032-016-0853-6

Jaroslav Tumas, Kotryna Kvederavičiūtė, M. Petrulionis, B. Kurlinkus, Arnas Rimkus, G. Sakalauskaitė, J. Cicenas, A. Šileikis

引用次数: 41

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

代谢组学在胰腺癌生物标志物研究中的应用

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Medical Oncology 医学-肿瘤学

CiteScore

4.20

自引率

2.90%

发文量

259

审稿时长

1.4 months

期刊介绍： Medical Oncology (MO) communicates the results of clinical and experimental research in oncology and hematology, particularly experimental therapeutics within the fields of immunotherapy and chemotherapy. It also provides state-of-the-art reviews on clinical and experimental therapies. Topics covered include immunobiology, pathogenesis, and treatment of malignant tumors.

期刊最新文献

Correction to: Lovastatin inhibits adipocyte-associated increased proliferation, EMT and aggressiveness of breast cancer cells. Correction to: Platinum nanoparticles in cancer therapy: chemotherapeutic enhancement and ROS generation. Thymoquinone decreases cell proliferation and immune evasion of breast cancer cells by reducing CD55 and CD114 levels. Correction to: Glucagon‑like peptide‑1 analogs activate AMP kinase leading to reversal of the Warburg metabolic switch in breast cancer cells. Correction to: Chemotherapy of breast cancer cells alters susceptibility to complement‑mediated opsonization and killing.